@article{mbs:/content/journal/jmm/10.1099/jmm.0.000477, author = "Brum, Alexandre Antunes and Rezende, Andrea de Fatima Silva and Brilhante, Francisco Silvestre and Collares, Thais and Begnine, Karine and Seixas, Fabiana Kommling and Collares, Tiago Veiras and Dellagostin, Odir Antônio and Azevedo, Vasco and Santos, Anderson and Portela, Ricardo Wagner and Borsuk, Sibele", title = "Recombinant esterase from Corynebacterium pseudotuberculosis in DNA and subunit recombinant vaccines partially protects mice against challenge", journal= "Journal of Medical Microbiology", year = "2017", volume = "66", number = "5", pages = "635-642", doi = "https://doi.org/10.1099/jmm.0.000477", url = "https://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.000477", publisher = "Microbiology Society", issn = "1473-5644", type = "Journal Article", keywords = "recombinant subunit vaccine", keywords = "caseous lymphadenitis", keywords = "DNA vaccine", keywords = "Corynebacterium pseudotuberculosis", abstract = " Purpose. We tested the efficacy of the esterase encoded by cp1002_RS09720 from Corynebacterium pseudotuberculosis in recombinant subunit and DNA caseous lymphadenitis (CLA) vaccines. This target was predicted as one of the best CLA vaccine candidates by mature epitope density analysis. Methodology. Gene cp1002_RS09720 was cloned into two different vectors (pAE for subunit vaccine and pTARGET for DNA vaccine). Four groups of 15 mice each were immunized with the recombinant esterase rCP09720 associated with aluminium hydroxide adjuvant (G1), pTARGET/cp09720 DNA vaccine (G2), a naked pTARGET (G3) or PBS as a negative control (G4). Immunization occurred in two doses intercalated by a 21 day interval. Twenty-one days after the last dose administration, animals were challenged with a virulent C. pseudotuberculosis MIC-6 strain. Results. G1 showed high levels of IgG1 and IgG2a on days 21 and 42 post-immunization and a significant level of IFN-γ (P<0.05), suggesting a Th1 response. The protection levels obtained were 58.3 and 16.6 % for G1 and G2, respectively. Conclusion. The subunit vaccine composed of the recombinant esterase rCP09720 and Al(OH)3 is a promising antigenic formulation for use against CLA.", }